학술논문

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
Document Type
Article
Author
Heier, Jeffrey SKhanani, Arshad MQuezada Ruiz, CarlosBasu, KarenFerrone, Philip JBrittain, ChristopherFigueroa, Marta SLin, HughHolz, Frank GPatel, VaibhaviLai, Timothy Y YSilverman, DavidRegillo, CarlSwaminathan, BalakumarViola, FrancescoCheung, Chui Ming GemmyWong, Tien YAbbey, AshkanAbdulaeva, ElmiraAbraham, PremaAdan Civera, AlfredoAgostini, HansjurgenAlezzandrini, ArturoAlfaro, VirgilAlmony, ArghavanAltay, LebrizAmini, PayamAntoszyk, AndrewAradi, EtelkaArias, LuisArnold, JenniferAsaria, RiazAstakhov, SergeiAstakhov, YuryAwh, Carl C.Balaratnasingam, ChandraBanerjee, SanjivBaumal, CarolineBecker, MatthiasBelfort, RubensBratko, GalinaBridges, William Jr. ZBrown, JaminBrown, David M.Budzinskaya, MariaBuffet, SylviaBurgess, StuartByon, IksooCagini, CarloCalzada, JorgeCameron, StoneCampochiaro, PeterCarlson, JohnCarneiro, AngelaChan, ClementChang, EmmanuelChang, AndrewChao, DanielChaudhry, NaumanChee, CarolineCheek, AndrewChen, Shih-JenChen, San-NiCheung, GemmyChexal, SaradhaChittum, MarkChow, DavidCole, AbosedeConnolly, BrianCornut, Pierre LoicCouvillion, StephenDanzig, CarlDaskalov, VesselinDessouki, AmrDevin, FrancoisDollin, MichaelDolz, RosaDowney, LouiseDreyer, RichardDugel, PravinEichenbaum, DavidEldem, BoraEngstrom, RobertEscobar, Joan JosepEter, NicoleFaber, David W.Falk, NaomiFeiner, LeonardFernandez Vega, AlvaroFerrone, PhilipFigueroa, MartaFine, HowardFineman, MitchellFox, Gregory M.Francais, CatherineFranco, PabloFraser-Bell, SamanthaFung, NicholasFurno Sola, FedericoGale, RichardGarcia-Layana, AlfredoGarcia-Layana, AlfredoGasperini, JulieGawecki, MaciejGhanchi, FaruqueGill, ManjotGiunta, MichelGlaser, DavidGoldstein, MichaellaGomez Ulla, FranciscoGomi, FumiGonzalez, VictorGraff, JordanGupta, SunilGuthoff, RainerGuymer, RobynHaas, AntonHampton, RobertHatz, KatjaHayashi, KenHeier, JeffreyHerba, EwaHershberger, VrindaHiggins, PatrickHolekamp, NancyHonda, ShigeruHoward, JamesHu, AllenHuddleston, StephenIida, TomohiroImaizumi, HirokoIto, YasuoIto, YasukiItty, SujitJavey, GolnazJavid, CameronKaga, TatsushiKaluzny, JakubKang, Se WoongKapoor, KapilKarabas, LeventKawasaki, TsutomuKelty, PatrickKerenyi, AgnesKhanani, ArshadKhoramnia, RaminKhurana, RahulKimura, KazuhiroKlein-Mascia, KendraKobayashi, NamieKodjikian, LaurentKoizumi, HidekiKokame, GreggKulikov, AlexeyKwong, HenryKwun, RobertLai, TimothyLai, Chi-ChunLalonde, LaurentLanzetta, PaoloLarsen, MichaelLavina, AdrianLee, Won KiLee, ji EunLee, SeongLevy, JaimeLindsell, LucasLiu, MimiLondon, NikolasLotery, AndrewLozano Rechy, DavidLuckie, AlanMaberley, DavidMaeno, TakatoshiMahmood, SajjadMakkouk, FuadMarcus, DennisMargherio, AlanMasse, HeleneMatsubara, HisashiMaturi, RajMehta, SoniaMenon, GeetaMentes, JaleMichels, MarkMitamura, YoshinoriMitchell, PaulMohamed, QureshMones, JordiMontemayor Lobo, RodrigoMontero, JavierMoore, JeffreyMori, RyusaburoMorori-Katz, HaiaMukherjee, RajMurata, ToshinoriMuzyka-Wozniak, MariaNardi, MarcoNarendran, NiroNicolo, MassimoNielsen, JaredNishimura, TetsuyaNoda, KousukeNowinska, AnnaOh, HideyasuOhr, MatthewOkada, AnnabelleOleksy, PiotrOno, ShinjiOzdek, SengulOzturk, BanuPablo, LuisPark, Kyu HyungParke, D. WilkiParravano, Maria CristinaPatel, PraveenPatel, ApurvaPatel, SunilPatel, SugatPauleikhoff, DanielPearce, IanPearlman, JoelPetkova, IvaPieramici, DantePozdeyeva, NadezhdaQureshi, JawadRaczynska, DorotaRamirez Estudillo, JuanRathod, RajivRazavi, HessamRegillo, CarlReilly, GayatriRicci, FedericoRich, RyanRomanowska-Dixon, BożenaRosenblatt, IritRuiz Moreno, Jose MariaSacu, StefanSaedon, HabibaSaeed, UsmanSagong, MinSakamoto, TaijiSandhu, SukhpalSararols, LauraSaravia, MarioSchadlu, RaminSchlottmann, PatricioSekiryu, TetsujuSeres, AndrásSermet, FigenShah, SumitShah, RohanShah, AnkurSheidow, ThomasSheth, VeeralShiragami, ChiekoSikorski, BartoszSilva, RufinoSingerman, LawrenceSisk, RobertSisk, RobertSørensen, Torben L.Souied, EricSpinak, David-JStaurenghi, GiovanniSteinmetz, RobertStoller, GlennStoltz, RobertSuan, EricSuner, IvanSuzanne, YzerTadayoni, RaminTakahashi, KanjiTakayama, KeiTaleb, AlexandreTalks, JamesTerasaki, HirokoThompson, JohnToth-Molnar, EditTran, KhoiTuli, RamanUchiyama, EduardoVajas, AttilaVan Lith-Verhoeven, JannekeVarsanyi, BalazsViola, FrancescoVirgili, GianniVogt, GáborVölker, MichaelWarrow, DavidWeber, PamelaWells, John A.Wickremasinghe, SanjeewaWieland, MarkWilliams, GeoffWilliams, ThomasWong, DavidWong, KingWong, JamesWong, IanWong, RobertWowra, BogumilWykoff, Charles C.Yamashita, AyanaYasuda, KanakoYilmaz, GurselYiu, GlennYoneda, AiYoon, Young HeeYoreh, BarakYu, HyeongGonYu, Seung YoungYurieva, TatianaZambrano, AlbertoZatorska, BarbaraZeolite, Carlos
Source
The Lancet; February 2022, Vol. 399 Issue: 10326 p729-740, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating intravitreal faricimab with extension up to every 16 weeks for neovascular age-related macular degeneration (nAMD).